The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)
Open accessAbstract
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the United States. Metabolic syndrome (MS) components are highly prevalent in NAFLD. Our aim is to assess the relationship of NAFLD and MS with long-term outcome of mortality.The Third National Health and Nutrition Examination Survey (NHANES) was utilized. NAFLD was diagnosed by ultrasound in the presence of hepatic steatosis and no other causes of chronic liver disease. History of MS and its components were obtained from self-reported NHANES questionnaires. Mortality was obtained from Mortality-Linkage File, through December 31, 2011. Chi-square test was used for categorical variables and Cox proportional models estimated hazard ratios with 95% confidence interval.NAFLD cohort (n = 3613) had a median age of 43 years, 73% white, and 50% male. NAFLD group with at least one MS condition was significantly older, had higher body mass index, more likely to have insulin resistance, and heart disease compared to NAFLD group without MS. Over 19-years of follow-up, 1039 people died. Compared to NAFLD patients without MS, presence of one MS component increased the risk of mortality at 8-year (2.6% vs 4.7%) and 16-year (6% vs 11.9%) (P < .001). After adjusting for socio-demographic factors, NAFLD with all MS components was associated with overall, cardiac and liver-mortality. Increased number of MS components was associated with lower survival (P < .0001).Patients with NAFLD and MS have higher mortality risk compared to NAFLD patients without MS. These NAFLD patients should be prioritized for the development of treatment regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conversely, having several cardiometabolic risk factors confers a greater risk of progressive liver damage and major adverse liver outcomes. 17,35”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [35]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Self-citationEckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,317
Grundy, S. M., Brewer, H. B., Cleeman, J. I., Smith, S. C., & Lenfant, C. (2004) · Circulation · doi:10.1161/01.cir.0000111245.75752.c6 · Cited by 5,982
Vernon, G. C., Baranova, A. V., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,116
Self-citationEkstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
Anstee, Q. M., Targher, G., & Day, C. P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.41 · Cited by 1,747
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe
Younossi, Z. M., Blissett, D. B., Blissett, R., Henry, L. L., Stepanova, M., Younossi, Y., Racila, A., Hunt, S., & Beckerman, R. (2016) · Hepatology · doi:10.1002/hep.28785 · Cited by 1,308
Self-citationNon-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
Yki‐Järvinen, H. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70032-4 · Cited by 1,296
Kotronen, A., & Yki‐Järvinen, H. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.147538 · Cited by 793
The Natural Course of Non-Alcoholic Fatty Liver Disease
Bertot, L. C., & Adams, L. A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050774 · Cited by 638
Cited by
Sorted by citations
Items 201–221 of 221
Zhang, P., Yang, S., Yu, P., Zeng, Y., Ye, C., Wang, P., Wang, M., Li, L., & Dong, X. (2024) · Research Square · doi:10.21203/rs.3.rs-4081675/v1
Economic and patient reported outcome burden of NAFLD
Golabi, P., & Younossi, Z. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00010-8
Self-citationClinical diagnosis and evaluation pathway
Lam, R., Banini, B. A., Do, A., & Lim, J. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00003-0
Chronische Erkrankungen – eine Versorgungsherausforderung
Eble, S. (2024) · Springer Reference Pflege, Therapie, Gesundheit · doi:10.1007/978-3-662-66798-9_10-1
Effects of Lifestyle Interventions on Metabolic Dysfunction-Associated Steatotic Liver Disease
Sharma, A. R., & Barb, D. (2025) · Springer eBooks · doi:10.1007/978-3-031-82888-1_10
A Gastroenterologist’s Approach to Improving Metabolic Health in MASLD
Razzak, I. A., Razzak, I. A., Noureddin, M., & Trivedi, H. D. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002210 · Cited by 1
Sinha, S., Yasmin, S., Patra, M., Sinha, N. K., & Ahmed, A. (2025) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1702_24
Li, Y., Song, G., Ma, J., Li, M., Tan, W., Chen, X., Liu, X., Yin, Y., Liu, S., Li, T., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7542509/v1
Roderburg, C., Krieg, S., Krieg, A., Demir, M., Luedde, T., Kostev, K., & Loosen, S. H. (2023) · Figshare · doi:10.6084/m9.figshare.22641091
Nishihara, T., Miyoshi, T., Nakashima, M., Takashi, M. I. K. I., Toda, H., Yoshida, M., Ichikawa, K., Osawa, K., & Yuasa, S. (2024) · Figshare · doi:10.6084/m9.figshare.26719074
Influence of Heart Function on the Assessment of MASLD Using Indocyanine Green Clearance
Salobir, J., Ranković, B., & Kaliterna, T. P. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08560-1
Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa
El‐Kassas, M., Spearman, C. W., Elsayed, M., & Younossi, Z. M. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.011 · Cited by 1
Self-citationAssociation of Metabolic Dysfunction-Associated Steatohepatitis with Metabolic-Related Diseases
Diamantopoulos, L. N., Kalligeros, M., Isaacs, S. D., & Mauricio, D. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.12.001
Marqueurs diagnostiques et pronostiques de la stéatohépatite métabolique
Coilly, A. (2019) · theses.fr (ABES) · doi:10.70675/488abf31z3acfz4f13z88e2zd974ef8b9b7b
Diversité des macrophages dans un modèle murin de stéatohépatite non alcoolique
Tran, S. (2019) · theses.fr (ABES) · doi:10.70675/22efc884z2788z43fazabc1zaeb115ea6833
Matboli, M., ELanwar, A., Khaled, R., Khaled, A., Eltantawy, E. H. B., Hamam, G. G., Ahmed, M. Y., Fouad, M., Tarek, A. A., El-Masry, M. M., et al. (2026) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-026-01181-3
Steatotic liver disease: a dynamic spectrum, not a static state
Spearman, C. W. (2026) · South African journal of gastroenterology and hepatology. · doi:10.36303/sajgh.4337
Kim, H., Yoo, J., Chang, Y. W., Jang, J. Y., Ryu, T., Jeong, S. W., Kim, S. G., Kim, Y. S., & Park, S. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1832416
Sharma, A. N., Bhagavatula, H., Mapundu, M. T., & Chimusa, E. R. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1803957 · Cited by 1
Dodd, T., Sharma, A., Amin, N., Tahan, V., Daglilar, E. S., & Duong, N. K. (2026) · Diseases · doi:10.3390/diseases14070243
The dynamic spectrum of steatotic liver disease: the global perspective
Younossi, Z. M., Zelber‐Sagi, S., Kalligeros, M., Wajcman, D. I., Henry, L. L., Grinshpan, L. S., Israelsen, M. E., Díaz, L. A., Fan, J., Arrese, M. A., et al. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01235-3
Self-citation
Metadata
- Authors
- Golabi, P., Otgonsuren, M., de Avila, L., Sayiner, M., Rafiq, N., & Younossi, Z. M.
- Affiliations
- Inova Health System (US)
- Corresponding author
- Younossi, Zobair M.
- Venue
- Medicine
- Published
- 2018-03
- Volume
- 97
- Issue
- 13
- Pages
- e0214
- ISSN
- 0025-7974 (ISSN-L)
- PMC
- PMC5895395
- OpenAlex
- W2794816422
- Cited by
- 221
- References
- 46
- Citations by year
- 2026: 16 · 2025: 20 · 2024: 32 · 2023: 25 · 2022: 33 · 2021: 36 · 2020: 24 · 2019: 24 · 2018: 9
- FWCI
- 18.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-sa
- Locations
- Medicine (publishedVersion, cc-by-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-sa)
- PubMed Central (publishedVersion, cc-by-sa)
- PubMed (publishedVersion)
- Funders
- Centers for Disease Control and Prevention
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- non-alcoholic fatty liver disease, metabolic syndrome, mortality risk, hepatic steatosis, insulin resistance, cardiovascular mortality, liver-related mortality, body mass index, long-term survival
- MeSH terms
- Adult, Cardiovascular Diseases, Female, Humans, Insulin Resistance, Male, Middle Aged, Nutrition Surveys, Risk Factors, United States, Comorbidity, Body Mass Index, Proportional Hazards Models, Age Distribution, Sex Distribution, Metabolic Syndrome, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review